clinical trial · NCT06918808
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
Direct Biologics, LLC·phase2·recruiting·n = 36
Perianal Fistula Due to Crohn's DiseaseDB-3QPlacebo
brief summary
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.
started
May 19, 2025
primary completion
Apr 30, 2026
completion
Oct 31, 2026
last updated
Feb 23, 2026
official title
A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol